ABCB1 p.Gly251Val
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 17848563
[PubMed]
Loo TW et al: "Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites."
No.
Sentence
Comment
94
Limited Proteolysis with Trypsin-HEK 293 cells expressing mutants G251V, L65R(TM1)/G251V, or wild-type P-gp were incubated in the presence or absence of 10 M cyclosporin A for 24 h. The membranes were then prepared as described previously (37) and suspended in Tris-buffered saline.
X
ABCB1 p.Gly251Val 17848563:94:66
status: NEWX
ABCB1 p.Gly251Val 17848563:94:83
status: NEW112 The positions of ⌬Y490 and G251V processing mutations are shown as gray circles.
X
ABCB1 p.Gly251Val 17848563:112:34
status: NEW165 Processing mutant G251V was chosen because it yields very low levels of mature 170-kDa protein and could be rescued by the presence of arginine in TM5 (I306R) or in TM6 (F343R) (21).
X
ABCB1 p.Gly251Val 17848563:165:18
status: NEW166 Accordingly, mutants L65R(TM1)/G251V, T199R(TM3)/G251V, I306R(TM5)/G251V (positive control), and A342R(TM6)/G251V (negative control) were constructed and expressed in HEK 293 cells. Whole cell SDS extracts were then subjected to immunoblot analysis. Fig. 4A shows that the presence of an arginine residue at positions 65(TM1), 199(TM3), and 306(TM5) promoted maturation of mutant G251V.
X
ABCB1 p.Gly251Val 17848563:166:31
status: NEWX
ABCB1 p.Gly251Val 17848563:166:49
status: NEWX
ABCB1 p.Gly251Val 17848563:166:67
status: NEWX
ABCB1 p.Gly251Val 17848563:166:108
status: NEWX
ABCB1 p.Gly251Val 17848563:166:380
status: NEW185 Arginines Disrupt Subset of P-gp Drug-binding Sites NOVEMBER 2, 2007•VOLUME 282•NUMBER 44 JOURNAL OF BIOLOGICAL CHEMISTRY 32047 By contrast, the presence of an arginine at position 342(TM6) did not rescue mutant G251V.
X
ABCB1 p.Gly251Val 17848563:185:227
status: NEW207 Effect of arginine mutations on maturation of the G251V and ⌬Y490 processing mutants.
X
ABCB1 p.Gly251Val 17848563:207:50
status: NEW208 Wild-type, G251V (A), or ⌬Y490 (B) P-gps containing mutations L65R(TM1), T199R(TM3), I306R(TM5), or A342R(TM6) were expressed in HEK 293 cells. Whole cell SDS extracts were subjected to SDS-PAGE on 5.5% gels and immunoblot analysis.
X
ABCB1 p.Gly251Val 17848563:208:11
status: NEW215 The positions of mature (170 kDa) and cross-linked (X-link) P-gps are indicated. Arginines Disrupt Subset of P-gp Drug-binding Sites 32048 prepared from cells expressing mutant G251V that were grown in the absence or presence of cyclosporin A, mutant L65R(TM1)/G251V, or wild-type P-gp.
X
ABCB1 p.Gly251Val 17848563:215:178
status: NEWX
ABCB1 p.Gly251Val 17848563:215:262
status: NEW227 Arginines Disrupt Subset of P-gp Drug-binding Sites NOVEMBER 2, 2007•VOLUME 282•NUMBER 44 JOURNAL OF BIOLOGICAL CHEMISTRY 32049 by immunoblot analysis. Fig. 7 shows that the mature 170-kDa protein in mutant G251V expressed in the presence of cyclosporin A was 100-fold more resistant to trypsin compared with the mutant expressed in the absence of drug substrate.
X
ABCB1 p.Gly251Val 17848563:227:222
status: NEW228 Similarly, the L65R(TM1)/G251V mutant and wild-type mature proteins were 100-fold more resistant to trypsin when compared with the 150-kDa protein of mutant G251V.
X
ABCB1 p.Gly251Val 17848563:228:25
status: NEWX
ABCB1 p.Gly251Val 17848563:228:157
status: NEW229 These results indicate that the L65R mutation converts mutant G251V into a more protease-resistant conformation.
X
ABCB1 p.Gly251Val 17848563:229:62
status: NEW240 Protease sensitivity of mutants G251V and L65R(TM1)/ G251V.
X
ABCB1 p.Gly251Val 17848563:240:32
status: NEWX
ABCB1 p.Gly251Val 17848563:240:53
status: NEW241 Membranes prepared from HEK 293 cells expressing mutant G251V that were grown in the absence or presence (ϩCyclo A) of cyclosporin A, mutant L65R(TM1)/G251V or wild-type P-gps were treated with various concentrations of TPCK-trypsin.
X
ABCB1 p.Gly251Val 17848563:241:56
status: NEWX
ABCB1 p.Gly251Val 17848563:241:157
status: NEW
PMID: 18596043
[PubMed]
Loo TW et al: "Arginines in the first transmembrane segment promote maturation of a P-glycoprotein processing mutant by hydrogen bond interactions with tyrosines in transmembrane segment 11."
No.
Sentence
Comment
2
To determine the mechanism of arginine rescue, we first tested the effects of introducing arginines at other positions in TM1 (residues 52-72) of a P-glycoprotein processing mutant (G251V) that is defective in folding and trafficking to the cell surface (20% maturation efficiency).
X
ABCB1 p.Gly251Val 18596043:2:182
status: NEW7 Mutations that removed hydrogen bond acceptors (Y950F/Y950A or Y953F/Y953A) in TM11 predicted to lie close to Arg-65 or Arg-68 inhibited maturation but did not affect maturation of the G251V parent.
X
ABCB1 p.Gly251Val 18596043:7:185
status: NEW21 It was found that the L65R mutation promoted maturation of P-gp processing mutants such as ⌬Y490 and G251V (9).
X
ABCB1 p.Gly251Val 18596043:21:108
status: NEW45 Accordingly,wefirstperformedarginine-scanningmutagenesis on TM1 of a P-gp processing mutant (G251V) to test their effects on maturation of the mutant.
X
ABCB1 p.Gly251Val 18596043:45:93
status: NEW53 Mutations were introduced into wild-type or processing mutant G251V (13) P-gp cDNAs as described previously (6, 15).
X
ABCB1 p.Gly251Val 18596043:53:62
status: NEW54 To perform arginine-scanning mutagenesis of TM1, the cDNA of mutant G251V P-gp was modified to create a set of mutants that contained one arginine at positions 52-72.
X
ABCB1 p.Gly251Val 18596043:54:68
status: NEW71 RESULTS Effect of TM1 Arginines on Maturation of Processing Mutant G251V-The crystal structure of the bacterial ABC drug transporter Sav1866 showed that the 12 TM segments of the transport complex surrounded a funnel-shaped chamber exposed to the extracellular environment (24).
X
ABCB1 p.Gly251Val 18596043:71:67
status: NEW91 Therefore, processing mutant G251V was selected for analysis as it shows inefficient maturation relative to wild-type P-gp (33).
X
ABCB1 p.Gly251Val 18596043:91:29
status: NEW92 The G251V mutation is located in the first intracellular loop (see Fig. 1A).
X
ABCB1 p.Gly251Val 18596043:92:4
status: NEW97 Immunoblot analysis of the G251V processing mutant, however, showed that the major product was the 150-kDa immature protein along with a minor amount (about 20%) of mature 170-kDa product (Fig. 2).
X
ABCB1 p.Gly251Val 18596043:97:27
status: NEW98 The most common effect of introducing arginines into mutant G251V was to reduce the level of mature P-gp (12 of 21 mutants).
X
ABCB1 p.Gly251Val 18596043:98:60
status: NEW100 Fig. 2 shows that the presence of an arginine at these positions reduced the level of mature product in mutant G251V from about 20% to less than 5% (Fig. 2B).
X
ABCB1 p.Gly251Val 18596043:100:111
status: NEW101 Introduction of arginines at positions 52 or 61 had little effect on maturation of G251V P-gp.
X
ABCB1 p.Gly251Val 18596043:101:83
status: NEW102 Introduction of arginines at the extracellular half of TM1 (positions 64, 65, 68, and 71), however, increased maturation of mutant G251V.
X
ABCB1 p.Gly251Val 18596043:102:131
status: NEW118 Mutants G251V, V53R/G251V (inhibited maturation) and M68R/G251V (enhanced maturation) were subjected endoglycosidase H or F digestion to determine whether the alterations in mobility of the mutant P-gps were indeed due to changes in the glycosylation state of the protein.
X
ABCB1 p.Gly251Val 18596043:118:8
status: NEWX
ABCB1 p.Gly251Val 18596043:118:20
status: NEWX
ABCB1 p.Gly251Val 18596043:118:58
status: NEW125 Because the M68R mutation was most efficient in promoting maturation of the G251V processing mutant, we tested whether it could also promote maturation of a different processing mutant.
X
ABCB1 p.Gly251Val 18596043:125:76
status: NEW131 Drug Rescue of P-gp G251V Arginine Mutants That Do Not Show Enhanced Maturation-If the arginine mutants that showed reduced maturation relative to the G251V (such as FIGURE 2.
X
ABCB1 p.Gly251Val 18596043:131:20
status: NEWX
ABCB1 p.Gly251Val 18596043:131:151
status: NEW132 Effect of TM1 arginine mutations on maturation of the G251V processing mutant.
X
ABCB1 p.Gly251Val 18596043:132:54
status: NEW133 A, immunoblot analysis of whole cell extracts of HEK 293 cells expressing no P-gp (Control), wild-type P-gp (Wild-type), or a G251V processing mutant containing the indicated TM1 arginine mutations.
X
ABCB1 p.Gly251Val 18596043:133:126
status: NEW138 Whole cell SDS extracts of HEK 293 cells expressing A52-tagged mutants G251V, V53R/G251V, or M68R/G251V were treated with endoglycosidase Hf (H),peptideN-glycosidaseF(F)ornoendoglycosidase(-).Equivalentamountsweresubjectedtoimmunoblot analysis.
X
ABCB1 p.Gly251Val 18596043:138:71
status: NEWX
ABCB1 p.Gly251Val 18596043:138:83
status: NEWX
ABCB1 p.Gly251Val 18596043:138:98
status: NEW142 Therefore, mutants showing reduced (T55R/G251V) or similar maturation efficiencies (H61R/G251V, M69R/G251V) to the G251V parent were expressed in the presence of 5 M cyclosporin A, 30 M verapamil, 5 M vinblastine, or 30 M rhodamine B.
X
ABCB1 p.Gly251Val 18596043:142:41
status: NEWX
ABCB1 p.Gly251Val 18596043:142:89
status: NEWX
ABCB1 p.Gly251Val 18596043:142:101
status: NEWX
ABCB1 p.Gly251Val 18596043:142:115
status: NEW143 These drug concentrations promoted rescue of the G251V parent so that mature (170 kDa) protein was the major product in the treated cells (Fig. 5).
X
ABCB1 p.Gly251Val 18596043:143:49
status: NEW144 By contrast, a mutant where the introduced arginine inhibited maturation of G251V (mutant T55R) could not be rescued with any of the drug substrates (Fig. 5).
X
ABCB1 p.Gly251Val 18596043:144:76
status: NEW146 For example, only cyclosporin A rescued mutant H61R/G251V (Fig. 5).
X
ABCB1 p.Gly251Val 18596043:146:52
status: NEW147 By contrast, all drugs except verapamil rescued mutant M69R/G251V (Fig. 5).
X
ABCB1 p.Gly251Val 18596043:147:60
status: NEW148 The effects of drug substrates on the expression of the other arginine/G251V mutants are summarized in Table 1.
X
ABCB1 p.Gly251Val 18596043:148:71
status: NEW150 Mutants V52R, L67R, and L70R resembled the parent (G251V) P-gp, as expression in any of the drug substrates promoted efficient maturation (mature P-gp became the major product) of the protein.
X
ABCB1 p.Gly251Val 18596043:150:51
status: NEW155 Effect of Suppressor Arginine Mutations on P-gp-Drug Interactions-Because mutant M68R/G251V showed efficient maturation (about 85%) when expressed in the absence of drug substrates (Fig. 2), we tested whether Arg-68 affected P-gp- drug interactions in disulfide protection assays using mutant L339C(TM6)/F728C(TM7) as described previously (9).
X
ABCB1 p.Gly251Val 18596043:155:86
status: NEW156 Because the G64R and V71R changes also promoted maturation of the G251V processing mutant (Fig. 2), we also introduced these mutations into the L339C(TM6)/F728C(TM7) mutant.
X
ABCB1 p.Gly251Val 18596043:156:66
status: NEW163 HEK 293 cells expressing mutants G251V, T55R/G251V, H61R/G251V, or M69R/G251V were treated with no drug (None), 5 M cyclosporin A (Cyclo), 30 M verapamil (Ver), 5 M vinblastine (Vin), or 30 M rhodamine B (Rhod) for 24 h. Whole cell extracts were then subjected to immunoblot analysis.
X
ABCB1 p.Gly251Val 18596043:163:33
status: NEWX
ABCB1 p.Gly251Val 18596043:163:45
status: NEWX
ABCB1 p.Gly251Val 18596043:163:57
status: NEWX
ABCB1 p.Gly251Val 18596043:163:72
status: NEW165 TABLE 1 Effects of drug substrates on the maturation of TM1 arginine mutants containing the G251V mutation Mutation (G251V ؉) No drug Cyclosporin A Verapamil Vinblastine Rhodamine None - 111a,c 111 111 11 V52R -a,b 111 111 111 11 V53R 2 - - - - G64R 2 - - - - T55R 2 - - - - L56R 2 - - - - A57R 2 - - - - A58R 2 - - - - I59R 2 - - - - I60R 2 - - - - H61R - 111 1 1 1 G62R 2 - - - - A63R 2 - - - - G64R 1 111 1 1 11 L65R 11 111 11 11 11 P66R 2 1 - - - L67R - 111 111 111 11 M68R 111 111 111 111 111 M69R - 111 - 11 111 L70R - 111 111 111 11 V71R 1 111 111 111 11 F72R 2 1 1 1 1 a Change in the amount of mature (170 kDa) protein in the presence of drug substrate relative to that in the absence of drug substrate.
X
ABCB1 p.Gly251Val 18596043:165:92
status: NEWX
ABCB1 p.Gly251Val 18596043:165:117
status: NEW167 c Change in the amount of mature (170 kDa) protein relative to the mutant G251V expressed in the absence of drug substrate.
X
ABCB1 p.Gly251Val 18596043:167:74
status: NEW208 Effect of TM11 Mutations on Rescue of Mutant G251V Containing the L65R and M68R Changes-One reason that Arg-68 caused the largest increase in maturation of mutant G251V is that the arginine residue may promote packing of the TM segments.
X
ABCB1 p.Gly251Val 18596043:208:45
status: NEWX
ABCB1 p.Gly251Val 18596043:208:163
status: NEW214 To test if Tyr-950 or Tyr-953 influences the ability of the M68R mutation to promote maturation of the G251V mutant, we introduced the Y950A or Y953A mutations into mutant M68R/ G251V mutant.
X
ABCB1 p.Gly251Val 18596043:214:103
status: NEWX
ABCB1 p.Gly251Val 18596043:214:178
status: NEW216 Fig. 8 shows the maturation efficiencies compared with the M68R/G251V parent.
X
ABCB1 p.Gly251Val 18596043:216:64
status: NEW218 Not all mutations in TM11, however, affected maturation of the M68R/G251V mutant.
X
ABCB1 p.Gly251Val 18596043:218:68
status: NEW219 The presence of mutations Q946A, M948A, M949A, F951A, or S952A did not appear to affect the maturation of the M68R/ G251V mutant (Fig. 8A, lanes 2-5, 7, and 8).
X
ABCB1 p.Gly251Val 18596043:219:116
status: NEW220 Because the L65R mutation also promoted maturation of mutant G251V, we tested whether the Y950A or Y953A mutations would have any effect on maturation of the L65R/G251V mutant.
X
ABCB1 p.Gly251Val 18596043:220:61
status: NEWX
ABCB1 p.Gly251Val 18596043:220:163
status: NEW222 In contrast, both Y950A and Y953A affected the maturation efficiency of the M68R/G251V mutant.
X
ABCB1 p.Gly251Val 18596043:222:81
status: NEW223 The Y950A and Y953A mutations did not affect maturation of the (G251V) parent (Fig. 8A, lanes 13 and 14) or wild-type P-gp (data not shown).
X
ABCB1 p.Gly251Val 18596043:223:64
status: NEW224 These results suggest that interactions between Arg-65(TM1) and Tyr-950(TM11), Arg-68(TM1) and Tyr-950(TM11), or Arg-68 (TM1) and Tyr953(TM11) may be responsible for the enhanced maturation of the G251V mutant.
X
ABCB1 p.Gly251Val 18596043:224:197
status: NEW229 Mutants L65R/G251V/Y950F, M68R/G251V/ Y950A/Y953A, and M68R/G251V/Y950F/Y953F were constructed, and the cDNAs were expressed in HEK 293 cells.
X
ABCB1 p.Gly251Val 18596043:229:13
status: NEWX
ABCB1 p.Gly251Val 18596043:229:31
status: NEWX
ABCB1 p.Gly251Val 18596043:229:60
status: NEW230 Only the Y950F change was introduced into the L65R/G251V mutant since the Y953A change did not affect maturation of the mutant (Fig. 8B, lane 4).
X
ABCB1 p.Gly251Val 18596043:230:51
status: NEW231 Immunoblot analysis shows the Y950A/Y953A and Y950F/Y953F changes in M68R/G251V (Fig. 8A, lanes 11 and 12) or Y950F change in L65R/G251V (Fig. 8B, lane 5) reduced maturation to levels similar to that observed in the G251V parent.
X
ABCB1 p.Gly251Val 18596043:231:74
status: NEWX
ABCB1 p.Gly251Val 18596043:231:131
status: NEWX
ABCB1 p.Gly251Val 18596043:231:216
status: NEW237 changes into the G251V parent did not affect its maturation efficiency (Fig. 8, A, lane 15, and B, lane 6).
X
ABCB1 p.Gly251Val 18596043:237:17
status: NEW239 DISCUSSION It was found that maturation of mutant G251V was not inhibited when arginines were introduced at many positions on the extracellular half of TM1.
X
ABCB1 p.Gly251Val 18596043:239:50
status: NEW261 Cyclosporin A and rhodamine B but not vinblastine or verapamil promoted maturation of the mutant G64R/ G251V (Table 1).
X
ABCB1 p.Gly251Val 18596043:261:103
status: NEW262 The H61R mutation appeared to perturb vinblastine interactions as expression in the presence of vinblastine did not promote maturation of the mutant H61R/G251V (Fig. 5).
X
ABCB1 p.Gly251Val 18596043:262:154
status: NEW264 Effect of TM11 mutations on maturation of M68R/G251V and L65R/G251V mutants.
X
ABCB1 p.Gly251Val 18596043:264:47
status: NEWX
ABCB1 p.Gly251Val 18596043:264:62
status: NEW265 A, HEK 293 cells were transfected with mutants M68R/G251V (lanes 2-12) or G251V (lanes 1, 13-15) containing the indicated TM11 mutations.
X
ABCB1 p.Gly251Val 18596043:265:52
status: NEWX
ABCB1 p.Gly251Val 18596043:265:74
status: NEW267 B, HEK 293 cells were transfected with mutants M65R/G251V (lanes 2-5) or G251V (lanes 1, 6) containing the indicated TM11 mutations.
X
ABCB1 p.Gly251Val 18596043:267:52
status: NEWX
ABCB1 p.Gly251Val 18596043:267:73
status: NEW276 Mutants H61R/G251V or M69R/G251V showed little drug rescue with verapamil (Fig. 5), and mutants G64R and M68R in a wild-type background showed reductions in apparent affinity for verapamil in ATPase assays (Fig. 7).
X
ABCB1 p.Gly251Val 18596043:276:13
status: NEWX
ABCB1 p.Gly251Val 18596043:276:27
status: NEW291 Shading on the P-gp amino acids represents the effects of arginine substitutions on maturation of mutant G251V; the white, gray, and black-filled circles represent inhibition, no effect, or promotion of maturation, respectively.
X
ABCB1 p.Gly251Val 18596043:291:105
status: NEW298 Some mutations such as G64R, L65R, M68R, and V71R actually promoted maturation of the G251V mutant.
X
ABCB1 p.Gly251Val 18596043:298:86
status: NEW299 The L65R and M68R mutations were particularly effective in promoting maturation as they increased maturation efficiency of the G251V mutant from about 20 to 60-85%.
X
ABCB1 p.Gly251Val 18596043:299:127
status: NEW302 Processing mutations such as G251V may alter the orientation of one or more TM segments in the membrane to interfere with subsequent packing of the TM segments at the interface between TMD1 and TMD2.
X
ABCB1 p.Gly251Val 18596043:302:29
status: NEW304 An alternative possibility to explain why the L65R and M68R mutations were particularly effective in promoting maturation of the G251V mutant is that they promoted packing of the TM segments by forming hydrogen bonds with Tyr-950 and/or Tyr-953 located in TM11.
X
ABCB1 p.Gly251Val 18596043:304:129
status: NEW306 Processing mutations such as G251V appear to act as thermodynamic hurdles to inhibit packing of the TM segments between TMD1 and TMD2 (6).
X
ABCB1 p.Gly251Val 18596043:306:29
status: NEW308 This possibility is supported by the observations that the conservative Y950F and Y953F mutations reduced maturation of the M68R/G251V mutant to levels observed with the G251V parent.
X
ABCB1 p.Gly251Val 18596043:308:129
status: NEWX
ABCB1 p.Gly251Val 18596043:308:170
status: NEW309 An arginine introduced at position 65 in TM1 only appeared to form a hydrogen bond with Tyr-950 as the Y950F mutation but not the Y953F change reduced maturation of the L65R/G251V mutant to levels observed with the G251V parent.
X
ABCB1 p.Gly251Val 18596043:309:174
status: NEWX
ABCB1 p.Gly251Val 18596043:309:215
status: NEW
PMID: 21177413
[PubMed]
Parveen Z et al: "Molecular dissection of dual pseudosymmetric solute translocation pathways in human P-glycoprotein."
No.
Sentence
Comment
314
The 132Arg mutant did not increase trafficking of the G251V background, whereas mutant 773Arg showed a complete trafficking deficiency.
X
ABCB1 p.Gly251Val 21177413:314:54
status: NEW
PMID: 21182301
[PubMed]
Loo TW et al: "The W232R suppressor mutation promotes maturation of a truncation mutant lacking both nucleotide-binding domains and restores interdomain assembly and activity of P-glycoprotein processing mutants."
No.
Sentence
Comment
42
In this study, the G251V processing mutant was used as a reporter molecule because it exhibits partial maturation (about 15% mature).
X
ABCB1 p.Gly251Val 21182301:42:19
status: NEW57 The red balls show the locations of Trp232 and the processing mutations at positions 251 (G251V), 490 (ΔY490), 709 (P709A), 722 (G722A), and 1260 (L1260A).
X
ABCB1 p.Gly251Val 21182301:57:90
status: NEW58 (B) HEK 293 cells were transfected with A52-tagged wild-type P-gp, mutants G251V, G251V/W232R, and G251V/ W232A,orplasmidvector(control).Wholecellextractsweresubjected to immunoblot analysis with monoclonal antibody against A52 or GAPDH.
X
ABCB1 p.Gly251Val 21182301:58:75
status: NEWX
ABCB1 p.Gly251Val 21182301:58:82
status: NEWX
ABCB1 p.Gly251Val 21182301:58:99
status: NEW67 Mutations were introduced into wild-type P-gp or processing mutants containing processing mutations in different domains (G251V in TMD1, ΔY490 in NBD1, P709A in the linker region, G722A in TMD2, or L1260A in NBD2) as described previously (28).
X
ABCB1 p.Gly251Val 21182301:67:122
status: NEW84 Baby hamster kidney (BHK) cells expressing A52-tagged wild-type P-gp or mutants G251V, G251V/W232R, W232R, W232A, N296A, E875A, or T945A were generated as described previously (25).
X
ABCB1 p.Gly251Val 21182301:84:80
status: NEWX
ABCB1 p.Gly251Val 21182301:84:87
status: NEW91 The G251V or L1260A processing mutations were introduced into Cys-less P-gp containing pairs of cysteines in different domains (L443C(NBD1)/ S909C(TMD2), L531C(NBD1)/C1074(NBD2), or C137(TMD1)/A935C(TMD2)) with or without the W232R mutation.
X
ABCB1 p.Gly251Val 21182301:91:4
status: NEW112 The W232R suppressor mutation that promotes maturation of the G251V processing mutant is located in TM4 of TMD1 (Figure 1A).
X
ABCB1 p.Gly251Val 21182301:112:62
status: NEW114 We tested whether a W232A change would also promote maturation of the G251V mutant.
X
ABCB1 p.Gly251Val 21182301:114:70
status: NEW117 The amount of mature P-gp relative to total (mature plus immature) was 70 ( 6% for mutant W232R/G251V and 92 ( 5% for wild-type P-gp.
X
ABCB1 p.Gly251Val 21182301:117:96
status: NEW118 By contrast, immature protein was the major product in mutants G251V (10 ( 4% mature) and G251V/W232A (13 ( 5% mature).
X
ABCB1 p.Gly251Val 21182301:118:63
status: NEWX
ABCB1 p.Gly251Val 21182301:118:90
status: NEW119 The results indicate that introduction of the arginine at 232 rather than removal of the tryptophan was responsible for the increase in maturation in mutant G251V.
X
ABCB1 p.Gly251Val 21182301:119:157
status: NEW123 We previously observed that W232R could rescue the ΔY490 (NBD1) and G251V (TMD1) P-gp processing mutants (42).
X
ABCB1 p.Gly251Val 21182301:123:74
status: NEW136 Therefore, some of the other Trp to Arg changes to flanking tryptophans could also promote maturation of G251V P-gp by helping to anchor other TM segments in the membrane.
X
ABCB1 p.Gly251Val 21182301:136:105
status: NEW137 Accordingly, mutants G251V/W212R(TM3), G251V/W315R- (TM5), G251V/W708R(TM7), and G251V/W855R(TM10) were constructed.
X
ABCB1 p.Gly251Val 21182301:137:21
status: NEWX
ABCB1 p.Gly251Val 21182301:137:39
status: NEWX
ABCB1 p.Gly251Val 21182301:137:59
status: NEWX
ABCB1 p.Gly251Val 21182301:137:81
status: NEW138 The W136R mutation inhibited maturation of G251V as shown previously (42), and the mutant was included in this study as a control (Figure 2B, lanes 8 and 9).
X
ABCB1 p.Gly251Val 21182301:138:43
status: NEW141 Mutant G251V/T55R(TM1) (Figure 2B, lanes 3 and 4) was included as a negative control because its maturation was unaffected by the presence of cyclosporin A (41).
X
ABCB1 p.Gly251Val 21182301:141:7
status: NEW143 It was found that none of the other Trp to Arg mutations promoted maturation of the G251V processing mutant in the absence of cyclosporin A (Figure 2B, lanes 8, 10, 14, 16, and 18).
X
ABCB1 p.Gly251Val 21182301:143:84
status: NEW155 To test if the W232R mutation restored domain-domain contacts, it was introduced into the G251V or L1260A processing mutants that also contained pairs of cysteines at the TMD1-TMD2 (C137(TMD1)/A935C(TMD2), NBD1-NBD2 (L531C(NBD1)/C1074(NBD2), or NBD1-TMD2 (L443C(NBD1)/S909C(TMD2) interfaces.
X
ABCB1 p.Gly251Val 21182301:155:90
status: NEW156 The G251V and L1260A parents were used because the G251V mutation is in the same domain as W232R (TMD1) whereas L1260A is in another domain (NBD2).
X
ABCB1 p.Gly251Val 21182301:156:4
status: NEWX
ABCB1 p.Gly251Val 21182301:156:51
status: NEW158 Introduction of the W232R mutation into all of the G251V (Figure 3A, lanes 3, 7, and 11) or L1260A (Figure 3B, lanes 3, 7, and 11) double-cysteine processing mutants restored maturation.
X
ABCB1 p.Gly251Val 21182301:158:51
status: NEW170 (B) Cells transfected with vector (control), A52-tagged wild-type P-gp (WT), mutant G251V cDNA containingT55R, or the indicated Trp to Arg mutation were expressed in the absence (-) or presence (þ) of 10 μM cyclosporin A (cyclo A).
X
ABCB1 p.Gly251Val 21182301:170:84
status: NEW181 To test for evidence of hydrogen bond interactions of W232R with residues in TM segments 5, 6, or 12, potential hydrogen bond partners (Thr294(TM5), Asn296(TM5), Ser298(TM5), Ser344(TM6), Gln347(TM6), Ser349(TM6), Ser351(TM6)), (Gln990(TM12), Ser992(TM12), or Ser993(TM12)) (see Figure 4A,B) were mutated to alanine in a G251V/W232R background.
X
ABCB1 p.Gly251Val 21182301:181:321
status: NEW184 It was observed that only one mutation in TM5 (N296A) inhibited maturation of the G251V/W232R mutant when it was expressed in the absence of cyclosporin A (Figure 4C, lane 7).
X
ABCB1 p.Gly251Val 21182301:184:82
status: NEW185 By contrast, mutation of potential hydrogen-bonding residues in TM6 (Ser344, Q347, S349, or Q351) or TM12 (Gln990, Ser992, or S993) to alanine did not affect maturation of G251V/W232R (Figure 4D).
X
ABCB1 p.Gly251Val 21182301:185:172
status: NEW186 Introduction of the N296A mutation into G251V/W232R(TM4) caused the mutant to behave in a fashion similar to the original FIGURE 3: Effect of W232R on cross-linking between domains of processing mutants.
X
ABCB1 p.Gly251Val 21182301:186:40
status: NEW187 Membranes were prepared from cells expressing P-gp processing mutants G251V ( W232R (A) or L1260A ( W232R (B) that also contained pairs of cysteines in various domains (L443C(NBD1)/S909C(TMD2), L531C(NBD1)/C1074(NBD2), C137(TMD1)/A935C(TMD2)).
X
ABCB1 p.Gly251Val 21182301:187:70
status: NEW192 FIGURE 4: Effect of mutating residues capable of forming hydrogen bonds with W232R on maturation of G251V.
X
ABCB1 p.Gly251Val 21182301:192:100
status: NEW194 (C) HEK 293 cells transfected with A52-tagged mutant G251V or G251V/ W232R containing alanine mutations in potential hydrogen-bonding residues in TM5 (T294A, N296A, S298A) or G251V/N296A were expressed in the absence (-) or presence (þ) of cyclosporin A (cyclo A).
X
ABCB1 p.Gly251Val 21182301:194:53
status: NEWX
ABCB1 p.Gly251Val 21182301:194:62
status: NEWX
ABCB1 p.Gly251Val 21182301:194:175
status: NEW196 (D) HEK 293 cells transfected with A52-tagged mutant G251V/W232R(TM4) containing mutations in potential hydrogen-bonding residues in TM6 (S344A, Q347A, S349A, S351A) or TM12 (Q990A, S992A, S993A) were cultured in the absence (-) or presence (þ) of cyclosporin A (cyclo A).
X
ABCB1 p.Gly251Val 21182301:196:53
status: NEW199 G251V parent.
X
ABCB1 p.Gly251Val 21182301:199:0
status: NEW200 Like the G251V parent (Figure 4C, lanes 1 and 2), the G251V/W232R/N296A mutant (Figure 4C, lane 7) showed about 15% maturation efficiency when expressed in the absence of drug substrates, and the mature 170 kDa P-gp was the major product when expressed in the presence of cyclosporin A (Figure 4C, lane 8).
X
ABCB1 p.Gly251Val 21182301:200:9
status: NEWX
ABCB1 p.Gly251Val 21182301:200:54
status: NEW201 Therefore, the presence of the N296A mutation prevented the ability of W232R to promote maturation of the G251V mutant.
X
ABCB1 p.Gly251Val 21182301:201:106
status: NEW202 Figure 4A (lanes 11 and 12) shows that the N296A change alone had little effect on the maturation characteristics of the G251V parent because it could still be rescued with cyclosporin A.
X
ABCB1 p.Gly251Val 21182301:202:121
status: NEW203 These results suggest that Arg232(TM4) promotes maturation of the G251V mutant through hydrogen bond interactions with Asn296(TM5) because the N296A mutation inhibited the ability of W232R to promote maturation of G251V (Figure 4C, lane 7).
X
ABCB1 p.Gly251Val 21182301:203:66
status: NEWX
ABCB1 p.Gly251Val 21182301:203:214
status: NEW207 To test if other mutations to Trp232 would promote maturation, it was changed to other residues capable (Asp, Asn, Ser, Tyr) or incapable (Ala, Gly, Ile, Phe) of forming hydrogen bonds in a G251V background.
X
ABCB1 p.Gly251Val 21182301:207:190
status: NEW210 No significant increase in maturation efficiency of G251V was observed when Trp232 was changed to amino acids that do not form hydrogen bonds (Ala, Gly, Ile, or Phe).
X
ABCB1 p.Gly251Val 21182301:210:52
status: NEW211 The pattern of rescue of the G251V/W232X mutants was consistent with the prediction that hydrogen bond interactions were responsible for the increase in maturation efficiency.
X
ABCB1 p.Gly251Val 21182301:211:29
status: NEW223 It was found that the FIGURE 5: Effect of different W232 mutations on maturation of G251V.
X
ABCB1 p.Gly251Val 21182301:223:84
status: NEW224 (A) HEK 293 cells expressing A52-tagged G251V containing mutations in W232 (-, no change) capable (Arg(R), Asp(D), Asn- (N), Ser(S), Tyr(Y)) or incapable (Ala(A), Gly(G), Ile(I), Phe(F)) of forming hydrogen bonds were subjected to immunoblot analysis with monoclonal antibody against A52 or GAPDH.
X
ABCB1 p.Gly251Val 21182301:224:40
status: NEW226 (B) The amount of mature P-gp (percent mature) relative to total P-gp (170 plus 150 kDa) in mutant G251V/W232X (X = W, R, D, N, S, Y, A, G, I, or F) is shown.
X
ABCB1 p.Gly251Val 21182301:226:99
status: NEW227 The results are the average values from three separate transfections ( SD. An asterisk indicates significant difference (P < 0.05) from parent (G251V).
X
ABCB1 p.Gly251Val 21182301:227:144
status: NEW238 A G251V/T945R/E875A mutant was constructed to test if removal of the negative charge would affect maturation.
X
ABCB1 p.Gly251Val 21182301:238:2
status: NEW243 Therefore, we tested the effect of reversing the charges by constructing mutant G251V/T945E/ E875R.
X
ABCB1 p.Gly251Val 21182301:243:80
status: NEW244 It was found that the T945E/E875R combination but not individual T945E or E875R mutations promoted maturation of G251V (Figure 7D).
X
ABCB1 p.Gly251Val 21182301:244:113
status: NEW256 FIGURE 7: Effect of mutations in Thr945 or Glu875 on the rescue of G251V P-gp or mutant TMD1 þ 2.
X
ABCB1 p.Gly251Val 21182301:256:67
status: NEW258 (C) Whole cell extracts from cells expressing A52-tagged mutant G251V (none) or G251V/T945R (T945R) with the indicated changes topotential hydrogen bondpartnersinTM10(lane4) orTM12(lanes 7-9) were subjected to immunoblot analysis with monoclonal antibody against A52 or GAPDH.
X
ABCB1 p.Gly251Val 21182301:258:64
status: NEWX
ABCB1 p.Gly251Val 21182301:258:80
status: NEW260 (D) Whole cell extracts of cells expressing A52-tagged G251V (none) or G251V mutants containing opposite charges at positions 945 and 875 (T945E/E875, T954E, or E875R) were subjected to immunoblot analysis with monoclonal antibody against A52 or GAPDH.
X
ABCB1 p.Gly251Val 21182301:260:55
status: NEWX
ABCB1 p.Gly251Val 21182301:260:71
status: NEW270 To test if rescue by an arginine suppressor mutation yielded an active transporter, we examined the ability of mutants G251V and G251V/W232R to confer resistance to cytotoxic compounds colchicine, paclitaxel, and vinblastine.
X
ABCB1 p.Gly251Val 21182301:270:119
status: NEWX
ABCB1 p.Gly251Val 21182301:270:129
status: NEW272 Stable BHK cell lines expressing wild-type P-gp or mutants G251V, W232R, or G251V/W232R were generated by cotransfecting P-gp cDNAs with pWL-neo vector followed by selection with G418.
X
ABCB1 p.Gly251Val 21182301:272:59
status: NEWX
ABCB1 p.Gly251Val 21182301:272:76
status: NEW279 Cells expressing mutant G251V showed almost no increase (P<0.05) in drug resistance compared to control cells.
X
ABCB1 p.Gly251Val 21182301:279:24
status: NEW280 This is to be expected since mutant G251V is a processing mutant in which the majority of P-gp is misfolded in the cell.
X
ABCB1 p.Gly251Val 21182301:280:36
status: NEW281 Introduction of the W232R mutation into G251V, however, yielded a functional P-gp.
X
ABCB1 p.Gly251Val 21182301:281:40
status: NEW282 Cells expressing mutant G251V/W232R were more resistant to colchicine (12-fold; P < 0.05) compared to cells expressing wild-type P-gp (9-fold) but were less resistant to vinblastine (3-fold (P < 0.05) versus 17-fold) and paclitaxel (18-fold (P < 0.05) versus 29-fold).
X
ABCB1 p.Gly251Val 21182301:282:24
status: NEW283 These results show that the W232R mutation restored maturation of mutant G251V P-gp to yield a functional transporter at the cell surface.
X
ABCB1 p.Gly251Val 21182301:283:73
status: NEW297 (A) Stable BHK cell lines expressing no P-gp (control), equivalent levels of wild type, mutants G251V, W232R, or G251V/W232R P-gp were incubated for 6 days in the presence of various concentrations of drug substrates vinblastine (gray bars), colchicine (white bars), or paclitaxel (black bars).
X
ABCB1 p.Gly251Val 21182301:297:96
status: NEWX
ABCB1 p.Gly251Val 21182301:297:113
status: NEW314 It also restored maturation of the G251V processing mutant to yield a functional transporter at the cell surface (Figure 9A).
X
ABCB1 p.Gly251Val 21182301:314:35
status: NEW386 Evidence for mobility of the TM segments is suggested by the large number of cross-links observed between TM segments in a cysteine mutagenesis study (51), that drug binding occurs through an induced-fit mechanism (93), that ATP hydrolysis can cause rotation of one or more helices (94), and that other residues at position 232 whose side chains are of different sizes and capable of forming hydrogen bonds (Asp, Ser, Tyr) could rescue G251V (Figure 5).
X
ABCB1 p.Gly251Val 21182301:386:436
status: NEW
PMID: 8995353
[PubMed]
Loo TW et al: "Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators."
No.
Sentence
Comment
64
In addition to the mutants G268V and ⌬Y490, we were able to facilitate processing of P-glycoproteins with mutations in the predicted transmembrane segments (TM1, G54V; TM5, G300V; TM7, A718L; and TM9, A841L), in the extracellular loops between transmembrane segments (G854V), in the cytoplasmic loops (G251V and W803A), in the nucleotide-binding domains (G427C and S434C), and in the linker region connecting the two halves of the molecule (E707A) (data not shown).
X
ABCB1 p.Gly251Val 8995353:64:309
status: NEW140 Another interesting observation is that misfolded mutants that are temperatureand glycerol-insensitive, such as G251V, G268V, and E707A could also be rescued by these drug substrates when expressed in either HEK 293 or NIH 3T3 cells (data not shown).
X
ABCB1 p.Gly251Val 8995353:140:112
status: NEW
PMID: 15530432
[PubMed]
Loo TW et al: "Thapsigargin or curcumin does not promote maturation of processing mutants of the ABC transporters, CFTR, and P-glycoprotein."
No.
Sentence
Comment
40
HEK293 cells expressing A52-tagged wild-type or mutant G251V P-gp were grown at 37 °C.
X
ABCB1 p.Gly251Val 15530432:40:55
status: NEW58 Mutations G251V and F804A are in the intracellular loops of the NH2- and COOH-terminal halves of P-gp, respectively.
X
ABCB1 p.Gly251Val 15530432:58:10
status: NEW70 Although the processing mutations (G251V, G300V, DY490, P709A, G722A, F804A, and P1194A) are located in different segments of P-gp, all the mutants could be rescued when expressed with drug substrates such as cyclosporin A.
X
ABCB1 p.Gly251Val 15530432:70:35
status: NEW71 A representative example is shown with mutant G251V.
X
ABCB1 p.Gly251Val 15530432:71:46
status: NEW72 HEK cells expressing mutant G251V were grown in the presence of various concentrations of cyclosporin A for 18 h at 37 °C.
X
ABCB1 p.Gly251Val 15530432:72:28
status: NEW76 To confirm that the cyclosporin A acted as a chemical chaperone to stabilize the mutant G251V protein resulting in decreased turnover, we performed pulse-chase studies (Fig. 2B).
X
ABCB1 p.Gly251Val 15530432:76:88
status: NEW77 HEK293 cells expressing mutant G251V were incubated with 35 [S]methionine for 20 min.
X
ABCB1 p.Gly251Val 15530432:77:31
status: NEW82 When synthesis of mutant G251V is carried out in the presence of 10 lM cyclosporin A, however, mature 170 kDa protein was readily detected after 1 h.
X
ABCB1 p.Gly251Val 15530432:82:25
status: NEW85 To determine if the mature 170 kDa protein of mutant G251V P-gp was active after rescue, we expressed the histidine-tagged wild-type or mutant G251V P-gp in HEK293 cells in the presence of 10 lM cyclosporin A for 18 h at 37 °C.
X
ABCB1 p.Gly251Val 15530432:85:53
status: NEWX
ABCB1 p.Gly251Val 15530432:85:143
status: NEW88 The mature form of mutant G251V was still active since it retained >90% of wild-type P-gp activity (not shown).
X
ABCB1 p.Gly251Val 15530432:88:26
status: NEW90 We then compared the abilities of cyclosporin A, thapsigargin, and curcumin to induce maturation of P-gp processing mutants G251V, G300V, DY490, P709A, G722A, F804A, and P1194A.
X
ABCB1 p.Gly251Val 15530432:90:124
status: NEW102 Accordingly, we stably expressed mutant G251V in baby hamster kidney (BHK) cells because it has been reported that curcumin can induce maturation Fig. 2. Effect of cyclosporin A on maturation of P-gp processing mutant G251V.
X
ABCB1 p.Gly251Val 15530432:102:40
status: NEWX
ABCB1 p.Gly251Val 15530432:102:218
status: NEW103 (A) HEK293 cells expressing the A52 epitope-tagged mutant G251V were incubated for 18 h at 37 °C in the presence of various concentrations of cyclosporin A (Cyclo A).
X
ABCB1 p.Gly251Val 15530432:103:58
status: NEW105 (B) HEK293 cells were transfected with A52-tagged G251V P-gp cDNA.
X
ABCB1 p.Gly251Val 15530432:105:50
status: NEW111 The BHK cells expressing mutant G251V were incubated with 10 lM cyclosporin A or various concentrations of thapsigargin (0-10 lM) or curcumin (0-30 lM).
X
ABCB1 p.Gly251Val 15530432:111:32
status: NEW112 Fig. 3B shows that in the absence of drug substrates, the major product of mutant G251V in BHK cells was the 150 kDa immature protein.
X
ABCB1 p.Gly251Val 15530432:112:82
status: NEW138 (B) BHK cells stably expressing A52-tagged mutant G251V were incubated for 18 h at 37 °C in the presence of 10 lM cyclosporin A (Cyclo) or various concentrations (lM) of thapsigargin or curcumin.
X
ABCB1 p.Gly251Val 15530432:138:50
status: NEW
PMID: 22232552
[PubMed]
Iram SH et al: "Mutation of Glu521 or Glu535 in cytoplasmic loop 5 causes differential misfolding in multiple domains of multidrug and organic anion transporter MRP1 (ABCC1)."
No.
Sentence
Comment
261
Thus, the P-glycoprotein processing mutant G251V/T55R is not rescued by any drug substrates, whereas another mutant G251V/H61R can be rescued by only a single substrate (cyclosporine A) (39).
X
ABCB1 p.Gly251Val 22232552:261:43
status: NEWX
ABCB1 p.Gly251Val 22232552:261:116
status: NEW
PMID: 24064216
[PubMed]
Kapoor K et al: "Mutations in intracellular loops 1 and 3 lead to misfolding of human P-glycoprotein (ABCB1) that can be rescued by cyclosporine A, which reduces its association with chaperone Hsp70."
No.
Sentence
Comment
402
Also G251V, which is in ICL1 and lies spatially close to Asp-164, is a well known processing mutant of P-gp (37).
X
ABCB1 p.Gly251Val 24064216:402:5
status: NEW
PMID: 24083983
[PubMed]
Loo TW et al: "Drug rescue distinguishes between different structural models of human P-glycoprotein."
No.
Sentence
Comment
15
Drug rescue of TM5 and TM9 G251V P-gp arginine mutants.
X
ABCB1 p.Gly251Val 24083983:15:27
status: NEW18 An asterisk indicates a significant difference from the amount of the mature form observed when the G251V parent was expressed without cyclosporine A (~5% mature).
X
ABCB1 p.Gly251Val 24083983:18:100
status: NEW23 Accordingly, the ability of drug substrates to promote maturation of a processing mutant (G251V) containing an arginine at each position in TM5 was used to map the locations of residues that faced the lipid bilayer (would prevent rescue) or the aqueous channel (would be rescued).
X
ABCB1 p.Gly251Val 24083983:23:90
status: NEW24 The rationale for using this assay was that drug substrates such as cyclosporine A can promote maturation of a P-gp processing mutant (G251V).14 The G251V mutation is located in the second intracellular loop (ICL2) (Figure 1A) and appears to trap P-gp in a partially folded conformation as a 150 kDa core-glycosylated protein.
X
ABCB1 p.Gly251Val 24083983:24:135
status: NEWX
ABCB1 p.Gly251Val 24083983:24:149
status: NEW25 Expression in the presence of a drug substrate induces G251V to complete the folding process to yield an active mature 170 kDa protein.15 Introduction of an arginine onto the lipid face of TM5 would inhibit drug rescue.
X
ABCB1 p.Gly251Val 24083983:25:55
status: NEW27 Examples of drug rescue of G251V and TM5 mutants G251V/I297R and G251V/S298R are shown in Figure 1B. When processing mutant G251V is expressed in the absence of cyclosporine A, the major product was the immature 150 kDa protein (~95% of total P-gp).
X
ABCB1 p.Gly251Val 24083983:27:27
status: NEWX
ABCB1 p.Gly251Val 24083983:27:49
status: NEWX
ABCB1 p.Gly251Val 24083983:27:65
status: NEWX
ABCB1 p.Gly251Val 24083983:27:124
status: NEW30 Arginine mutations were then introduced into each position of TM5 or TM9 in the G251V background.
X
ABCB1 p.Gly251Val 24083983:30:80
status: NEW
PMID: 24349290
[PubMed]
Chufan EE et al: "Multiple transport-active binding sites are available for a single substrate on human P-glycoprotein (ABCB1)."
No.
Sentence
Comment
220
The same residues studied in the present work were mutated to arginine by Loo and coworkers [38]; they found these mutations promote or have a neutral effect on maturation of a Pgp processing mutant (G251V) defective in folding, also confirming that these residues are in the drug translocation pathway and/or drug-binding pocket of Pgp.
X
ABCB1 p.Gly251Val 24349290:220:200
status: NEW